Clinical Trial

A Randomized Controlled Trial of Robotic Support for Enhanced Later Life (RoSELL)

Study acronym: RoSELL
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare the efficacy of a personalized, co-designed robot interaction against a standardized, fixed robot interaction for reducing loneliness, depression, as well as improving self-agency and quality of life in older adults. This is a three-arm randomized controlled trial. The study will be conducted at a community center in Fuzhou, China, with 100 participants aged 65+ recruited from the facility. The participants will be randomly assigned to one of three conditions: (1) Co-designed robot (CL) group receiving a personalized robot interaction with a structured co-design ceremony; (2) Standard robot (SL) group interacting with an identical robot without personalization features; or (3) An attention-controlled usual care (CU) group. The intervention comprises 16 sessions (two weekly 20-minute sessions over eight weeks). The primary outcomes are loneliness and depressive symptoms. Secondary outcomes include general self-efficacy, quality of life, as well as staff and participants' perceptions of the robot. Mechanism measures (i.e., engagement, self-disclosure) and manipulation checks (e.g., perceived personal role) will be employed to elucidate the underlying theoretical pathways. Data will be collected at baseline (T0), after the initial 2-week co-design period (T1), post-intervention (T2, Week 8), and at 1-month (T3) and 3-month (T4) follow-ups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-01.
Trial Details
NCT Number NCT07102017
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Loneliness, Well-Being, Psychological, Depression - Major Depressive Disorder
Enrollment 90 participants
Start Date 2025-05-06
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-19